Our Vision
To transform the wellbeing of patients with chronic respiratory disease
Our Mission
To develop innovative, safe, well-tolerated and effective drugs that alleviate suffering of patients with debilitating and often fatal respiratory conditions
Translating a ground-breaking discovery in CK1 δ/ε biology into new medicines
TianLi Biotech is a start-up company that develops novel proprietary small molecule inhibitors of CK1 δ/ε with a primary focus in respiratory diseases but also exploring potential applications in oncology, kidney and liver fibrosis.
TianLi Biotech is based on an original discovery from Professor Alastair Stewart (Department of Biochemistry and Pharmacology, The University of Melbourne) and supports discovery and development programs led by Professor Alastair Stewart and Professor Spencer Williams (School of Chemistry, The University of Melbourne).
The technology is focused on modulating the contribution of casein kinases in respiratory inflammatory/fibrotic conditions, such as idiopathic pulmonary fibrosis, severe asthma and chronic obstructive pulmonary. These conditions are lead indications for intervention by small molecule inhibitors of casein kinase 1 delta/epsilon (CK1 δ/ε).
Meet the Team
Board
Dr. BOWEN ZHANG
Dr. Bowen Zhang is president and General Manager of Beijing No. 1 Biotechnology Group Co., Ltd since 2003. He brings over 30 years of experience from diverse roles within the biopharmaceutical industry.
He has been instrumental in implementing crucial reforms, including relocating and reconstructing the factory site, resulting in GMP certification and sustained sales growth.
Dr. Zhang's leadership has facilitated the development of a comprehensive system for R&D, cooperation, manufacture, and marketing of pharmaceutical and healthcare products.
He holds a diploma in pharmaceutical science from Peking University, an MBA from the Chinese Academy of Social Sciences, and is currently pursuing a Doctor of Professional Studies in Business at Fordham University and Peking University.
Mr. GUOWEI JIN
Mr. Guowei Jin is the chief consultant at Beijing No. 1 Biotechnology Group Co., Ltd. He has extensive experience in pharmaceutical research, investment, and management.
From 1982-1987, at the China Academy of Chinese Medical Sciences, he had a pivotal role in the pioneering artemisinin discovery, which earned the 2015 Nobel Prize in Physiology of Medicine.
He also completed notable "Dihydroartemisinin and Tablet Research" which gained numerous awards. Between 1987 and 2003, Mr. Jin was integral to the CITIC Group, focusing on investment, trade, and management.
From 2003-2015, Mr. Jin's responsibilities included development and management at Zhongguancun Development Hi-Tech Incubator Co., Ltd., where he also served as Deputy General Manager and Chairman of Zhongguancun Life Science Park Biomedical Technology Incubator Co., Ltd.
Dr. YAN HAN
Dr. Yan Han is the CEO of TianLi Biotech. She brings over 20 years of global management experience across markets in China, Australia, and India.
As the founder and chairperson of Think Culture Foundation and chairperson for International Business at Topline Consulting Group, Dr. Yan's expertise spans strategic planning, cross-cultural business communications, joint ventures and alliances, new market development, and operational management.
A driving force behind innovative transformations and digitally advanced practices, Dr. Yan leverages her extensive experience in multinational corporations. She holds a Doctor of Professional Studies degree in Business and Economics from Fordham University (Gabelli school of business) and an Executive MBA from Peking University (Guanghua School of Management).
Prof. ALASTAIR STEWART
Prof. Alastair Stewart holds the Chair of Pharmacology and Therapeutics at the University of Melbourne and serves as the Director of the ARC Industrial Transformation Training Centre for Personalised Therapeutics Technologies (ARC CPTT).
His research interests lie in drug targeting for remodelling and inflammation.
Apart from academia, Prof. Stewart plays significant roles in professional associations, serving as President of the Asia Pacific Federation of Pharmacologists and holding previous positions on committees of the Respiratory Structure Function assembly, the American Thoracic Society, and the Executive and Council of Thoracic Society of Australia and New Zealand. He is also a former Director of Research Australia.
The Management Team
Dr. YAN HAN – CEO
Dr. Yan Han has more than 20 years of management expertise in multinational organisations on a global level.
She has facilitated countless successful projects in both for-profit and not-for-profit contexts and has continuously replicated similar success in her managerial roles internationally across China, Australia, and India.
She also brings her wealth of experience in additional areas such as cross-cultural and cross-discipline facilitation, brand development, strategic insight formulation, as well as innovation and digital advancement practices.
Prof. ALASTAIR STEWART – CSO
Prof. Alastair Stewart has extensive experience in the field of respiratory and inflammation research.
He has published over 220 papers, has had numerous patents proceed to grant and has served on various peer review committees for the NHMRC and the scientific advisory boards of several Australian Medical Research Institutes.
His editorial roles include Chief Editor of the Translational Pharmacology section of Frontiers in Pharmacology and Senior Associate Editor of the American Society for Mechanical Engineering Journal (ASME), Journal of Engineering and Science in Medical Diagnostics and Therapy.
Prof. Stewart is developing and applying the concept of mechanopharmacology in drug discovery and in the development of sub-acute, high-content screening technology.
Mr. PAUL LIU – CFO
With over 25 years of financial expertise, Mr. Paul Liu is a seasoned professional in management and project accounting, with a keen understanding of global financial dynamics through his dealings with overseas and local boards.
His strengths lie in navigating complex alliance contracting environments and managing diverse stakeholders, consistently delivering positive outcomes. Mr. Liu brings a solid background in project commercial management and finance controlling, supported by advanced skills in systems like SAP, XERO, QB and Microsoft.
Analytical and proactive, Mr. Liu has a proven track record of enhancing business processes and driving financial success. His proficiency spans budgeting, reporting, auditing, and various financial functions across IT, HR, Admin, Finance & Accounting areas.
In addition to his role at TianLi Biotech, Mr. Liu leads his own practice at M&T Tax and Financial Solutions, further showcasing his dedication and expertise in financial management.
Scientific Advisory Board
Professor Alastair Stewart (CSO)
Professor Ian Glaspole (Respiratory Medicine)
Dr. Mark Graham (Toxicology)
Professor Clive Page (Pharmacology)
Dr. John Pritchard (Formulation and Device)
Dr. Martine Keenan (MED CHEM)
Dr. Lorna Mitchell (MED CHEM)
WuxiIND (Regulatory Team)
For information on TianLi Biotech and the company development program please contact us via:
info@tlbiotech.com.au
Follow us on LinkedIn
© Copyright 2023 -
TianLi Biotech
Website designed by
Fifth Castle Media